Understand Treatment Options for BPDCN
BPDCN Treatment Just Changed: Here’s What Patients Need to Know
A second targeted therapy was FDA-approved in 2026. One of the specialists who led both trials explains what it means for you.
The FDA approved a second targeted therapy for BPDCN in May 2026, giving patients and doctors a choice that didn’t exist before. But knowing a new option exists is only the first step. Knowing how to ask about it, evaluate it, and decide what’s right for your situation is where this conversational comes in.
Dr. Naveen Pemmaraju of UT MD Anderson Cancer Center, the physician who led the clinical trials for both FDA-approved BPDCN targeted therapies, joins patient advocate Andrew Schorr for a free, in-depth conversation built for patients and care partners navigating this disease right now.
Program Topics
- Learn what changed and why it matters: Two targeted therapies are now FDA-approved for BPDCN. Get a plain-language breakdown of how each one works and what the approval means for patients.
- Understand your treatment options side by side: Dr. Pemmaraju explains the difference between tagraxofusp (ELZONRIS) and pivekimab sunirine (DECNUPAZ), the side effects to know about, and how to work with your doctor on deciding the right approach for you.
- Know which questions to bring to your next appointment: From biomarker testing to stem cell transplant eligibility, learn what to ask your care team and when to ask it.
- Find out where the research is headed: Hear what combination approaches are showing promise in clinical trials now, and why trials are worth considering at every stage, not just at relapse.
Visit Our Partners
Thank you to Blood Cancer United for their partnership. They are here for you with information about clinical trials, resources, and dedicated support through their Information Specialists.
Program Sponsor
Thank you to our sponsor for its support of our independent patient education program. The Patient Story retains full editorial control over all content.